Essential Site Maintenance: Authorea-powered sites will be updated circa 15:00-17:00 Eastern on Tuesday 5 November.
There should be no interruption to normal services, but please contact us at [email protected] in case you face any issues.

loading page

Efficacy and Safety of Oral Pentoxifylline in the Treatment and Recovery of Patients with Moderate to Severe COVID-19 Infection Treated with Routine Protocols: A Randomized Controlled Clinical Trial
  • +9
  • Farnoosh Seirafianpour,
  • Simin Almasi,
  • Sara Sadeghi,
  • Rohollah Valizadeh,
  • Taghi Riahi,
  • Zeynab Yassin,
  • Shiva Javadi,
  • M. Ranjbar,
  • Mahin Makiani,
  • Manizheh Goudarzi,
  • Fatemeh Sadat Hosseini-Baharanchi,
  • Azadeh Goodarzi
Farnoosh Seirafianpour
Iran University of Medical Sciences
Author Profile
Simin Almasi
Iran University of Medical Sciences
Author Profile
Sara Sadeghi
Iran University of Medical Sciences
Author Profile
Rohollah Valizadeh
Iran University of Medical Sciences
Author Profile
Taghi Riahi
Iran University of Medical Sciences
Author Profile
Zeynab Yassin
Iran University of Medical Sciences
Author Profile
Shiva Javadi
Iran University of Medical Sciences
Author Profile
M. Ranjbar
Iran University of Medical Sciences
Author Profile
Mahin Makiani
Iran University of Medical Sciences
Author Profile
Manizheh Goudarzi
Iran University of Medical Sciences
Author Profile
Fatemeh Sadat Hosseini-Baharanchi
Iran University of Medical Sciences
Author Profile
Azadeh Goodarzi
Iran University of Medical Sciences

Corresponding Author:[email protected]

Author Profile

Abstract

Backgrounds: The absence of a gold-standard treatment for COVID-19 infection encourages clinicians to benefit from multipotential medications in the treatment of COVID-19. The current controlled randomized clinical trial tried to evaluate the efficacy and safety of pentoxifylline (PTX) as an adjuvant therapy in moderate to severe COVID-19 infection. Methods: In this randomized controlled clinical trial, two groups of hospitalized patients with moderate to severe COVID-19 infection were randomized by the block randomization method to either receive standard protocol therapy or standard protocol therapy plus pentoxifylline 400 mg TDS for 14 days. Results: The results showed a greater improvement in the proinflammatory biomarkers in the intervention group. Oxygen saturation, hemoglobin, and platelet levels were also improved to a higher level among pentoxifylline recipients. The mortality rate was reported 4% and 32% in the intervention and control groups, respectively. One out 13 patients with severe COVID-19 infection expired in the intervention group, while 20 out of 28 patients expired in the control group, showing about 10 times higher mortality rate compared to the pentoxifylline recipients. Conclusion: Pentoxifylline increased the survival rate of COVID-19 patients and played as a preventive role for COVID-related mortality and morbidity such as acute respiratory distress syndrome.